Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 408.18 USD 0.72% Market Closed
Market Cap: 105.1B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

Net Margin
Vertex Pharmaceuticals Inc

-4.5%
Current
29%
Average
-7.6%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4.5%
=
Net Income
-479.8m
/
Revenue
10.6B

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.2B USD
-5%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
318.1B USD
9%
US
Amgen Inc
NASDAQ:AMGN
142.2B USD
13%
US
Gilead Sciences Inc
NASDAQ:GILD
117.1B USD
0%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
135.7B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
34%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36.2B EUR
-14%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.3B USD
-16%
Country US
Market Cap 105.2B USD
Net Margin
-5%
Country FR
Market Cap 6T USD
Net Margin
-21 040%
Country US
Market Cap 318.1B USD
Net Margin
9%
Country US
Market Cap 142.2B USD
Net Margin
13%
Country US
Market Cap 117.1B USD
Net Margin
0%
Country US
Market Cap 94.1B EUR
Net Margin
-392%
Country AU
Market Cap 135.7B AUD
Net Margin
18%
Country US
Market Cap 78.7B USD
Net Margin
34%
Country US
Market Cap 39.3B EUR
Net Margin
-33%
Country NL
Market Cap 36.2B EUR
Net Margin
-14%
Country US
Market Cap 31.3B USD
Net Margin
-16%
No Stocks Found

Vertex Pharmaceuticals Inc
Glance View

Market Cap
105.2B USD
Industry
Biotechnology
Economic Moat
Narrow

In the bustling landscape of biotechnology, Vertex Pharmaceuticals Inc. stands out as a dynamic powerhouse that has deftly carved a niche in the complex domain of genetic therapies. Founded in 1989, the company initially embarked on a mission to revolutionize drug discovery through a cutting-edge rational drug design approach. Armed with an innovative spirit and a focus on niche markets, Vertex turned its attention towards cystic fibrosis—a life-shortening genetic disorder affecting the lungs and digestive system. The company’s breakthrough came with the development and approval of the first therapies that address the underlying cause of cystic fibrosis, rather than just alleviating symptoms. These products, including Kalydeco and Trikafta, have repositioned Vertex from a scrappy biotech upstart to a dominating force in the drug market as these life-changing treatments not only improve patient outcomes but also command premium pricing. Vertex’s business model brilliantly capitalizes on its deep investment in research and development, allowing it to maintain a robust pipeline that promises ongoing growth. By channeling a substantial portion of its revenue back into R&D, Vertex seeks to extend its therapeutic successes beyond cystic fibrosis into other serious diseases with high unmet needs, such as sickle cell disease and beta-thalassemia. This strategic reinvestment supports a cyclical framework of innovation—capitalize on current successes while laying down the groundwork for future therapies. With a singular focus on specialty drugs that target specific genetic mutations or pathways, Vertex not only thrives on the immediate financial returns of its blockbuster drugs but continually invests in scientifically ambitious endeavors, thus reinforcing its status as a leader in the precision medicine sector.

VRTX Intrinsic Value
260.53 USD
Overvaluation 36%
Intrinsic Value
Price

See Also

Discover More
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-4.5%
=
Net Income
-479.8m
/
Revenue
10.6B
What is the Net Margin of Vertex Pharmaceuticals Inc?

Based on Vertex Pharmaceuticals Inc's most recent financial statements, the company has Net Margin of -4.5%.